Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease
Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease Infilbray is a once-daily oral medicine that acts across the blood-brain barrier, targeting devastating neurological manifestations associated with GD3 GD3…
